Nplate bone marrow stimulator approved to treat low platelet counts

FDA approved Amgen’s Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder ITP that can lead to serious bleeding. – The U.S. Food and Drug Administration approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.

Gender may play role in kidney transplant

Female who receive a kidney from a male donor are more likely to reject the kidney or graft, suggested by the Swiss researchers. – There are more chances of kidney rejection in a woman who gets a kidney from a male donor, revealed by Swiss researchers in a research paper published in the current issue of the medical journal The Lancet from UK.

GVAX cancer immunotherapy improves prostate cancer survival

Interim analysis supports continuation of Cell Genesys’ VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer – Cell Genesys, Inc. (Nasdaq: CEGE) announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue, as GVAX cancer immunotherapy improves prostate cancer patients survival.

Cancer stem cells causing childhood leukemia found

A new study of four-year-old twin girls has identified a stem cell that is the root cause of childhood cancer – Acute lymphoblastic leukaemia (ALL). – A breakthrough study of identical twins has for the first time confirmed the existence of cancer stem cells that cause the most common form of childhood cancer, acute lymphoblastic leukaemia (ALL) ? backing evidence that this childhood cancer starts in the womb. The research should lead to less aggressive treatment for childhood ALL and provides the hope of new, more effective drugs.

Test for targeted therapy in acute myeloid leukemia

Researchers have discovered that a particular hormone is responsible for driving a cancer enzyme to cause an often deadly red blood cell cancer, Polycythemia vera.
– An Oregon Health & Science University Cancer Institute researcher has discovered that a particular hormone is responsible for driving a cancer enzyme to cause an often deadly red blood cell cancer.

Gleevec improves special leukemia in children

Gleevec has been shown to improve outcomes for children with Philadelphia chromosome-positive acute lymphoblastic leukemia.
– Gleevec, the targeted cancer pill that has saved more than 100,000 lives, now is saving more children with a dire leukemia, as well as preventing disease progression with long term use in adults with chronic myeloid leukemia.

Understanding chronic myeloid leukemia

Researchers have discovered abnormal cells in the early stem cell population in Chronic myeloid leukemia CML patients.
– Oregon Health & Science University Cancer Institute researchers have opened a new window into the roots of chronic myeloid leukemia (CML). “We are looking under the surface of CML to understand better where the cancer is coming from. We have discovered abnormal cells in the early stem cell population in some CML patients, which don’t belong to the CML clone. These are abnormal cells that are not part of the CML clone,” said Thomas Bumm, M.D., OHSU Cancer Institute member.